Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
BACKGROUND:The AKT/mTORC1/S6K pathway is frequently overstimulated in breast cancer, constituting a promising therapeutic target. The benefit from mTOR inhibitors varies, likely as a consequence of tumour heterogeneity, and upregulation of several compensatory feed-back mechanisms. The mTORC1 downst...
Main Authors: | Elin Karlsson, Ivana Magić, Josefine Bostner, Christine Dyrager, Fredrik Lysholm, Anna-Lotta Hallbeck, Olle Stål, Patrik Lundström |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4689523?pdf=render |
Similar Items
-
Clinical potential of the mTOR effectors S6K1, S6K2 and 4EBP1 in breast cancer
by: Karlsson, Elin
Published: (2014) -
The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations : a crosstalk with potential to predict tamoxifen resistance in breast cancer
by: Bostner, Josefine
Published: (2013) -
Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer
by: Savitha Sridharan, et al.
Published: (2020-02-01) -
Role of PI3K/mTOR/S6K1 signaling pathway in Diabetic Nephropathy
by: Chu-Yun Cheng, et al.
Published: (2011) -
Sulforaphane regulates AKT/mTOR/S6K pathway in human breast cancer cells
by: Chiao-Ying Lien, et al.
Published: (2014)